H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Opko Health (OPK – Research Report) today and set a price target of $3.00. The company’s shares closed last Friday at $1.99.
Chen covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals, Clearside Biomedical, and First Wave Bio. According to TipRanks, Chen has an average return of -29.8% and a 25.40% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Opko Health with a $2.50 average price target, implying a 25.63% upside from current levels. In a report released on August 4, Barrington also maintained a Buy rating on the stock with a $2.00 price target.
See the top stocks recommended by analysts >>
OPK market cap is currently $1.54B and has a P/E ratio of -7.14.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OPK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OPKO Health, Inc. engages in the provision of healthcare services. It operates through the Diagnostics and Pharmaceuticals segments. The Diagnostics segment comprises clinical laboratory operations which acquired through the Bio-Reference and point-of-care operations. The Pharmaceuticals segment includes the pharmaceutical operations acquired in Chile, Mexico, Ireland, Israel, and Spain; and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.
Read More on OPK:
